+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Healthy Volunteer

Healthcare professionals often face severe stress, which can lead to sick leave and affect their well-being. This research aims to evaluate whether a five-week internet-based compassion course can help reduce stress of conscience and work-related stress, while improving professional quality of life and self-compassion. The study compares this compassion course with a general internet-based cognitive behavioral therapy CBT stress management course and a waitlist group. Participants will be randomly assigned to one of three groups a therapist-guided internet compassion course, a therapist-guided general internet CBT stress management course, or a waitlist for 10 weeks followed by the general CBT course. Both courses are structured self-help programs lasting five weeks, including weekly reports and therapist feedback delivered online. The compassion course focuses on compassion-focused therapy methods, while the CBT course uses traditional CBT techniques. Throughout the study, participants will complete assessments at baseline, 5, 10, and 15 weeks, and again at 6 months. These assessments measure changes in stress of conscience, professional quality of life, work-related stress, and self-compassion. Data are collected through self-assessment forms, and the study tracks progress over time to understand the effects of the courses. The total participation time spans up to 6 months to monitor longer-term outcomes and maintenance of benefits.

Age: 20Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an artificial intelligence AI decision support system called Dermalyser to help primary care physicians distinguish between skin cancer and benign skin lesions. This multicenter randomized controlled trial is conducted at about 30 primary care centers across Sweden, Germany, Scotland, the Netherlands, and Australia. The study aims to assess the accuracy, reliability, and clinical usefulness of Dermalyser in real clinical settings where most patients with skin lesions are managed. Participants will be assessed at primary care centers randomized to either use Dermalyser as a complementary diagnostic tool or follow the standard clinical procedure without AI support. After reaching half of the planned enrollment, centers switch from one phase to the other. Physicians can choose to use Dermalyser when they find it indicated, but the final clinical decision about lesion management remains with the physician. Both groups will be followed for up to five years to track tumor diagnoses, proportions of skin cancer versus benign lesions, and related health outcomes. During the study, participants will have their skin lesions evaluated according to either the AI-supported or standard procedure. The primary outcome measure is the proportion of skin cancers detected within six months of enrollment. Researchers will monitor morbidity and mortality related to skin cancer and compare differences between the groups. Participation may last up to five years with follow-up to assess diagnostic outcomes and safety. The study is sponsored by Linkping University.

Age: 18Years +All GendersPhase Not Applicable
8 locations
C

Actively Recruiting

Researchers are evaluating whether a shorter period of immunotherapy after radical surgery is as effective as the standard longer treatment for patients with high-risk malignant skin melanoma. This study focuses on people aged 18 and older who have undergone surgery for stage IIb-c, III, or IV melanoma. The goal is to see if six months of immunotherapy can prevent cancer recurrence as well as the current 12-month treatment, potentially reducing side effects, hospital visits, and healthcare costs. The study is a randomized phase 3 trial conducted internationally with patients followed for up to five years. Participants will receive immunotherapy drugs, currently nivolumab or pembrolizumab, given intravenously. They are randomly assigned to either six months experimental group or 12 months standard group of treatment. Patients who had immunotherapy before surgery neoadjuvant treatment can also join, with their pre-surgery treatment time added to the post-surgery treatment. Medical exams and imaging scans CT or PET-CT are done at the start, six months, and 36 months, along with regular check-ups over three years. If cancer returns, additional tests and treatments are planned based on medical team decisions. During the study, participants will have scheduled visits for physical exams, blood tests, and scans to monitor their health and detect any recurrence. Researchers will measure relapse-free survival and distant metastatic-free survival at two years as primary outcomes, with overall survival and health economic effects also assessed over five years. Safety monitoring includes standard care practices and follow-up for up to five years. The study aims to confirm if shorter immunotherapy duration maintains the same outcomes while benefiting patients and healthcare systems.

Age: 18Years +All GendersPhase 3
26 locations
S

Actively Recruiting

This research investigates the use of superparamagnetic iron oxide SPIO nanoparticles as a tracer for delayed sentinel lymph node dissection d-SLND in women with breast conditions where immediate axillary surgery is not needed. This includes patients with a preoperative diagnosis of ductal carcinoma in situ DCIS, unclear suspicious breast lesions, or those planned for risk-reducing mastectomy. The study aims to assess the effectiveness and accuracy of the delayed SLND approach, allowing some patients to avoid upfront surgery in the axilla. Participants receive an injection of SPIO near the breast lesion during their primary breast surgery, either up to 24 hours before or during the operation. If the final pathology shows invasive breast cancer, a second operation is performed to remove the sentinel lymph nodes SLNs using either SPIO or a radioactive tracer, depending on random assignment. The procedure involves multiple steps including detection of magnetic and radioactive signals, incision, SLN identification, and removal. Blue dye may also be used to assist in locating the nodes. During the study, patients undergo initial breast surgery with SPIO injection and magnetic signal detection but no immediate SLN removal. If invasive cancer is found, the delayed SLND procedure is done later with additional tracers. Researchers measure detection rates of SLNs, concordance between methods, and malignancy rates. Safety and procedure success are closely monitored. The study includes a control group receiving standard upfront SLND, and participants are followed until the study ends in 2027.

Age: 18Years +FEMALEPhase 3
9 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
U

Actively Recruiting

Generalized anxiety symptoms are common and often treated in primary health care. This research aims to better understand how adults with these symptoms experience anger and how healthcare professionals perceive and manage anger in these patients. The study focuses on adults with symptoms of generalized anxiety regardless of a formal diagnosis and explores the connection between anxiety and anger through qualitative interviews. The study involves interviewing two groups patients aged 18 or older with symptoms of generalized anxiety and healthcare professionals who work with these patients in primary care settings. There is no intervention or treatment applied, as it is an observational study. Interviews are guided by questionnaires and are audio recorded and transcribed for analysis. Participants will complete background questionnaires and take part in interviews about their experiences and attitudes towards anger in the context of generalized anxiety. The data will be analyzed thematically to identify patterns and insights. Researchers will evaluate the experiences of anger up to six months after enrollment. The total study duration varies per participant, focused on collecting qualitative data without active treatment or follow-up procedures.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Spontaneous intracerebral hemorrhage ICH is a serious type of stroke with high death and disability rates. Researchers are investigating whether a structured treatment package called a Care Bundle can improve the 3-month outcomes for patients with acute ICH compared to standard care. The study is an international, multicenter, parallel, cluster-randomized clinical trial focusing on implementing this Care Bundle in high-income countries, building on results from previous trials mostly done in low- and middle-income countries. The Care Bundle includes early intensive blood pressure lowering, treatment of fever and high blood sugar, rapid reversal of oral anticoagulation, and timely referrals to intensive care or neurosurgery when needed. Hospitals are randomized in batches through three phases usual care, randomized evaluation of the Care Bundle versus usual care, and a post-implementation follow-up where all hospitals apply the Care Bundle. Each batch lasts 18 months, with 6 months per phase, and the overall study rollout spans 2.5 years. Participants are adults aged 18 or older diagnosed with spontaneous ICH confirmed by imaging within 24 hours of symptom onset. During the study, patient management details and outcomes will be closely monitored, including brain imaging, blood pressure, glucose levels, and functional status. The primary outcome is functional recovery measured by a utility-weighted modified Rankin Scale score at 180 days. Secondary outcomes include disability, death, and health-related quality of life. The study also collects data on treatments and care decisions to evaluate the Care Bundles effectiveness and sustainability.

Age: 18Years +All GendersPhase 4
54 locations
C

Actively Recruiting

Researchers are evaluating the outcomes of one-visit versus two-visit root canal treatments endodontics for infected necrotic teeth in general dental practices. This randomized study aims to compare these treatment methods by assessing periapical health one and four years after the procedures. It also seeks to evaluate the quality of root fillings and the frequency of complications associated with each approach. A pilot study will help refine the protocol before the full multi-center study involving several clinics across five counties in Sweden. Participants will be randomly assigned to one of two groups one receiving root canal treatment completed in a single visit, and the other undergoing treatment spread over two visits. Both treatment approaches follow typical clinical practice without a strict protocol. In the two-visit group, the first visit includes cleaning, shaping, and medication placement with temporary sealing, followed by root filling and restoration in the second visit at least one week later. In the one-visit group, the treatment may be completed in the first visit or spread across another visit as clinically appropriate. Throughout the study, participants will be contacted by phone 5 to 7 days after treatment to check for complications, and a clinic visit will be scheduled one month post-treatment for further assessment. Clinical controls including intra-oral radiographs will be performed at one and four years after treatment completion to evaluate periapical health, with radiographs reviewed by blinded independent observers. The study will also track post-operative pain, medication use, tooth survival, and complications over both short and long-term follow-up periods.

Age: 18Years +All GendersPhase Not Applicable
7 locations

1-10 of 20

1